当前位置: X-MOL 学术Cell Host Microbe › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The success of SARS-CoV-2 vaccines and challenges ahead
Cell Host & Microbe ( IF 30.3 ) Pub Date : 2021-07-14 , DOI: 10.1016/j.chom.2021.06.016
Kanta Subbarao 1
Affiliation  

The rapid and remarkably successful development, manufacture, and deployment of several effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is now tempered by three key challenges. First, reducing virus transmission will require prevention of asymptomatic and mild infections in addition to severe symptomatic infections. Second, the emergence of variants of concern with mutations in the S protein’s receptor binding domain increases the likelihood that vaccines will have to be updated because some of these mutations render variants less optimally targeted by current vaccines. This will require coordinated global SARS-CoV-2 surveillance to link genotypes to phenotypes, potentially using the WHO’s global influenza surveillance program as a guide. Third, concerns about the longevity of vaccine-induced immunity highlight the potential need for re-vaccination, depending on the extent to which the virus has been controlled and whether re-vaccination can target those at greatest risk of severe illness. Fortunately, as I discuss in this review, these challenges can be addressed.



中文翻译:

SARS-CoV-2 疫苗的成功和未来的挑战

几种有效的严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 疫苗的快速且非常成功的开发、制造和部署现在面临三个关键挑战。首先,除了严重的有症状感染外,减少病毒传播还需要预防无症状和轻度感染。其次,与 S 蛋白受体结合结构域突变有关的变体的出现增加了疫苗必须更新的可能性,因为其中一些突变使当前疫苗不太理想地靶向变体。这将需要协调的全球 SARS-CoV-2 监测,以将基因型与表型联系起来,并可能以世卫组织的全球流感监测计划为指导。第三,对疫苗诱导免疫的持久性的担忧凸显了重新接种疫苗的潜在需求,这取决于病毒得到控制的程度以及重新接种疫苗是否可以针对那些最有可能患上严重疾病的人。幸运的是,正如我在这篇评论中所讨论的,这些挑战是可以解决的。

更新日期:2021-07-15
down
wechat
bug